Sun Pharma Q2 profit falls 36% on Rs 1,269 crore of one-offs
Sun Pharma's September-quarter profit fell 36.4% to Rs 1,988.53 crore as antitrust and Organon deal costs hit, while revenue rose to Rs 16,199 crore.
Sun Pharmaceutical Industries reported a 36.36% fall in consolidated net profit to Rs 1,988.53 crore for the July to September quarter of FY27, from Rs 3,124.95 crore a year earlier, while revenue from operations rose to Rs 16,198.71 crore from Rs 14,478.31 crore, Medical Dialogues reported. The drop is explained by about Rs 1,269 crore of exceptional charges, mostly a US antitrust settlement and the costs of the planned Organon acquisition. The figures are the company's own and come from one outlet's summary of the results.
What the results say
The headline numbers are straightforward. Net profit was Rs 1,988.53 crore, against Rs 3,124.95 crore a year earlier, a fall of 36.36%. Revenue from operations grew to Rs 16,198.71 crore from Rs 14,478.31 crore, which works out to about 11.9% growth by this site's own calculation. Total expenses rose to Rs 12,287.83 crore from Rs 10,780.62 crore.
So the business grew while the bottom line shrank. The gap is the exceptional items. Exceptional charges are costs that the company treats as outside its normal operations, and they are reported on a separate line so that readers can see the underlying trend. Here they were about Rs 1,269 crore in total.
The one-offs behind the drop
Two items make up the exceptional charges, according to the report. About Rs 923 crore went to settling a US litigation over alleged generic-drug price fixing, an antitrust case in which drug companies were accused of coordinating prices on some generics. About Rs 346 crore went to costs of the proposed acquisition of Organon, a US-based healthcare company. Management said more deal-related costs may arise before the acquisition closes.
The Organon deal is still subject to customary closing conditions and is expected to close by early 2027, the report says. The summary does not state the deal's price, and this site has not opened a second source on it.
A rough reading of the numbers: adding the Rs 1,269 crore of exceptional charges back to the reported profit gives about Rs 3,257 crore. That figure is only a sketch. It ignores tax on the charges, and it is not a number the company has reported, so it should not be read as an adjusted profit. What it does show is that, without the one-offs, profit would probably have been close to last year's level and not down by more than a third.
How the business performed
India formulations, the company's home market for branded generics, grew 17.3% to Rs 5,552.3 crore, or 34.5% of consolidated sales. Global innovative medicines, which are the patented specialty products sold mainly outside India, rose 6.9% to about $356 million, or 21.1% of sales. Emerging markets made up 20.7% of consolidated revenue.
Growth in innovative medicines came from both US and non-US markets, the report says. Among the products it names are Ilumya and others. Ilumya, a psoriasis drug, has now been approved in the US for adults with active psoriatic arthritis, according to the summary. Sun also licensed lerodalcibep, a PCSK9 inhibitor (a type of cholesterol-lowering drug), for markets outside the US and China.
Managing Director Kirti Ganorkar said the quarter's performance was driven by "strong momentum in India, emerging markets and the rest of the world". That is a management view. The report does not give figures for EBITDA (earnings before interest, tax, depreciation and amortisation), US specialty sales, research spending or full-year guidance, so those cannot be assessed here.
Reading the quarter: competing ways to see it
There are two sensible ways to read these results, and they lead to different conclusions. One view is that a 36% fall in profit is a real cost to shareholders, whatever its label, because a company that keeps booking one-offs on acquisitions and settlements is paying real money. The other is that the settlement closes a legal risk and the deal costs are a one-time step toward a larger business, so the underlying operations are healthy: revenue is up almost 12% and India sales are up 17.3%.
Both can be true. What the report does not tell us is how large the remaining legal and deal costs will be, which is the uncertain part. Management says more deal-related costs may come, but gives no estimate.
It also helps to separate what Sun reports from what an outside analyst might compute. Sun's numbers are the company's own results. Outside estimates of adjusted profit, deal value or synergies would come from brokers, and none appears in the report.
What it means for readers
For an investor in the stock, the quarter shows why headline profit and operating strength can diverge. Reported profit fell by more than a third; sales rose by roughly one-eighth. Anyone judging the company has to decide how much weight to give one-off costs, and nothing here is advice on buying, selling or holding.
For patients and the health system, the more relevant point is the India business: formulations are the branded medicines sold in Indian pharmacies, and 17.3% growth suggests continued demand. Sun's other news this week, covered in a separate story today, is its CDSCO approval for a generic oral semaglutide, which adds to its portfolio of diabetes and weight medicines. Elets eHealth reports that Sun's two existing semaglutide injections, Noveltreat and Sematrinity, had sales of Rs 19 crore and Rs 16 crore up to September 2026. That is about Rs 35 crore combined against quarterly revenue of Rs 16,199 crore, so semaglutide is still a very small part of the business today, though the company's chairman has said even a few percent of the patient pool would be "a very, very large product".
A second thing worth noticing is the balance between the three regions the report names. India is the largest single block at 34.5% of sales and the fastest growing of the segments listed, with 17.3% growth against 6.9% for global innovative medicines. A company that depends on branded generics at home for a third of its sales is exposed to Indian pricing rules and to competition from domestic rivals, while its specialty business depends on a small number of patented products, such as Ilumya, whose US approvals drive growth. Each leg carries its own risks, and the report does not discuss them.
The simulator below lets you test the effect of one-off charges on profit using this quarter's numbers. It adds the charges back with no tax effect, so it is a simplification and not an adjusted profit.
What to watch next
Watch for the Organon deal's closing conditions and any further transaction costs, which management says may arise before the expected early-2027 close. Watch also for the next quarter's exceptional items, to see whether the antitrust settlement was the last large charge. Finally, watch how Sun prices and launches its new oral semaglutide and whether India formulations keep growing at around 17%.
Key takeaways
- Sun Pharma's consolidated net profit fell 36.36% to Rs 1,988.53 crore in the quarter, while revenue rose about 11.9% to Rs 16,198.71 crore, according to Medical Dialogues.
- Exceptional charges of about Rs 1,269 crore, mainly Rs 923 crore for a US antitrust settlement and Rs 346 crore for Organon deal costs, explain the drop.
- India formulations grew 17.3% to Rs 5,552.3 crore, and global innovative medicines rose 6.9% to about $356 million.
- The Organon deal is expected to close by early 2027, and management says more deal costs may come before then.
Sources
- [Elets eHealth: Sun Pharma oral semaglutide gets CDSCO approval](https://ehealth.eletsonline.com/2026/11/sun-pharma-oral-semaglutide-cdsco-approval/)
- [Medical Dialogues: Sun Pharma Q2 profit falls 36%, revenue rises to Rs 16,199 crore](https://medicaldialogues.in/news/industry/pharma/sun-pharma-q2-profit-falls-36-revenue-rises-to-rs-16199-crore-182609)
Tags: Sun Pharma Quarterly results Pharma Organon Antitrust